OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Trent on the Role of Adjuvant Imatinib in GIST

January 6th 2021

Jonathan C. Trent, MD, PhD, discusses the role of adjuvant imatinib in gastrointestinal stromal tumors.

Dr. Sequist on the Importance of Broad Molecular Testing in Lung Cancer

January 5th 2021

Lecia V. Sequist, MD, MPH, discusses the importance of implementing broad molecular testing in lung cancer.

Dr. Gupta on Developing Biomarkers of Lack of Response in Urothelial Carcinoma

January 5th 2021

Shilpa Gupta, MD, discusses the need to develop biomarkers of lack of response to immunotherapy in urothelial carcinoma.

Dr. Ailawadhi on the Integration of Selinexor in Relapsed/Refractory Multiple Myeloma

January 5th 2021

Sikander Ailawadhi, MD, discusses the integration of selinexor into the treatment landscape of relapsed/refractory multiple myeloma.

Dr. Andorsky on the Results of a Subgroup Analysis of the MAGNIFY Trial in NHL

January 5th 2021

David J. Andorsky, MD, discusses the results of a subgroup analysis of the phase 3b MAGNIFY trial in relapsed/refractory non-Hodgkin lymphoma.

Dr. Barr on Exploring U2 Plus Venetoclax in Relapsed/Refractory CLL

January 4th 2021

Paul M. Barr, MD, discusses exploring umbralisib plus ublituximab plus venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Al-Sawaf on the Next Steps of the CLL14 Trial in CLL

January 4th 2021

Othman Al-Sawaf, MD, a physician with the University Hospital of Cologne in Germany, discusses the next steps of the CLL14 trial in chronic lymphocytic leukemia.

Dr. Rogers on Assessing MRD After Obinutuzumab/Ibrutinib/Venetoclax in CLL

January 4th 2021

Kerry Rogers, MD, discusses the minimal residual disease assessment component of a phase 2 trial evaluating obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia.

Dr. Grothey on the Results of the ANCHOR-CRC Trial in BRAF V600E-Mutant mCRC

January 4th 2021

Axel Grothey, MD, discusses the results of the phase 2 ANCHOR-CRC trial in patients with BRAF-mutant metastatic colorectal cancer.

Dr. Corr on the Rationale to Evaluate WNT Inhibition in Gynecologic Cancers

January 4th 2021

Bradley Corr, MD, discusses the rationale to evaluate WNT pathway inhibition in gynecologic cancers.

Dr. Ruan on Updated Results With Lenalidomide/Rituximab in MCL

January 4th 2021

Jia Ruan, MD, PhD, discusses updated results with the combination of lenalidomide and rituximab in mantle cell lymphoma.

Dr. Siddiqi on the Rationale to Evaluate CAR T-Cell Therapy in CLL

December 23rd 2020

Tanya Siddiqi, MD, discusses the rationale to evaluate CAR T-cell therapy in chronic lymphocytic leukemia.

Dr. Barr on the Need to Develop Novel Therapies in CLL

December 23rd 2020

Paul M. Barr, MD, discusses the need to develop novel therapies in chronic lymphocytic leukemia.

Dr. Allan on the Safety Profile of Ibrutinib in High-Risk CLL

December 23rd 2020

John N. Allan, MD, discusses the safety profile of ibrutinib in high-risk chronic lymphocytic leukemia.

Dr. Powles on the Rationale to Evaluate ctDNA in High-Risk Muscle-Invasive Bladder Cancer

December 22nd 2020

Thomas Powles, MBBS, MRCP, MD, discusses the rationale to evaluate circulating tumor DNA in high-risk muscle-invasive bladder cancer.

Dr. Al-Sawaf on the Limitations of Continuous Therapy Administration in CLL

December 22nd 2020

Othman Al-Sawaf, MD, discusses the limitations of continuous therapy administration in chronic lymphocytic leukemia.

Dr. Pusztai on the Promise of ctDNA Assays in Breast Cancer

December 22nd 2020

Lajos Pusztai, MD, DPhil, discusses the promise of circulating tumor DNA assays in breast cancer.

Dr. Kim on the Utility of Atezolizumab/Bevacizumab in HCC

December 21st 2020

Joseph Kim, MD, on the utility of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Dr. Patel Ongoing Research Efforts in Pancreatic Cancer

December 21st 2020

Reema A. Patel, MD, discusses ongoing research efforts in pancreatic cancer.

Dr. Marabelle on Preliminary Findings With SO-C101 in Advanced Solid Tumors

December 21st 2020

Aurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.